Abstract
Recombinant adeno-associated viral vectors (rAAV) have now been used in several clinical trials to treat a variety of diseases, and are currently the preferred choice of many investigators in the field, due to both their low pathogenicity and immunogenicity compared with other viral vectors, as well as localized long-term gene expression, despite their limitations of DNA size packaging and speed of expression. Recently, a number of advances have led to new generations of rAAV vectors, with improved features. This review addresses the various strategies employed to such effect, namely exploring distinct serotype tropisms, the production of mosaic and chimeric capsids, the selection of vectors through directed evolution, the development of self-complementary vectors, the use of pharmacological adjuvants and the induction of specific capsid mutations. Such approaches are expected to help the establishment of rAAV-based clinical gene therapy in the near future.
Keywords: Viral vectors, adeno-associated virus, directed evolution, selective mutagenesis, gene transfer, safety, efficacy.
Current Gene Therapy
Title:Advances in Recombinant Adeno-Associated Viral Vectors for Gene Delivery
Volume: 13 Issue: 5
Author(s): Hilda Petrs-Silva and Rafael Linden
Affiliation:
Keywords: Viral vectors, adeno-associated virus, directed evolution, selective mutagenesis, gene transfer, safety, efficacy.
Abstract: Recombinant adeno-associated viral vectors (rAAV) have now been used in several clinical trials to treat a variety of diseases, and are currently the preferred choice of many investigators in the field, due to both their low pathogenicity and immunogenicity compared with other viral vectors, as well as localized long-term gene expression, despite their limitations of DNA size packaging and speed of expression. Recently, a number of advances have led to new generations of rAAV vectors, with improved features. This review addresses the various strategies employed to such effect, namely exploring distinct serotype tropisms, the production of mosaic and chimeric capsids, the selection of vectors through directed evolution, the development of self-complementary vectors, the use of pharmacological adjuvants and the induction of specific capsid mutations. Such approaches are expected to help the establishment of rAAV-based clinical gene therapy in the near future.
Export Options
About this article
Cite this article as:
Petrs-Silva Hilda and Linden Rafael, Advances in Recombinant Adeno-Associated Viral Vectors for Gene Delivery, Current Gene Therapy 2013; 13 (5) . https://dx.doi.org/10.2174/15665232113136660028
DOI https://dx.doi.org/10.2174/15665232113136660028 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Reposition of the Fungicide Ciclopirox for Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Bee Venom: Its Potential Use in Alternative Medicine
Anti-Infective Agents Targeted Therapy for Advanced Renal Cell Cancer: Cytokines and Beyond
Current Pharmaceutical Design Molecular Imaging at Tohoku University: From Cancer to Neuroreceptors
Current Medical Imaging Design, Synthesis and Antitumor Activity of Quinazoline Derivatives Bearing 2,3-Dihydro-indole or 1,2,3,4-Tetrahydroquinoline
Letters in Drug Design & Discovery Negative Regulation of NEDD8 Conjugation Pathway by Novel Molecules and Agents for Anticancer Therapy
Current Pharmaceutical Design A Wnt-ow of Opportunity: Targeting the Wnt/β-Catenin Pathway in Breast Cancer
Current Drug Targets Fasciola Hepatica Extract Induces Cell Death of Mammalian Cells
Anti-Infective Agents Intraperitoneal Chemotherapy as First-Line Treatment in the Management of Epithelial Ovarian Cancer
Mini-Reviews in Medicinal Chemistry Advanced Microfluorescence Methods in Monitoring Intracellular Uptake of “Antisense” Oligonucleotides
Current Organic Chemistry New Potential Pharmaceutical Applications of Hypericum Species
Mini-Reviews in Medicinal Chemistry Natural DNA Intercalators as Promising Therapeutics for Cancer and Infectious Diseases
Current Cancer Drug Targets Lipid-Based Drug Delivery Systems for Cancer Treatment
Current Drug Targets Molecular Mechanisms of Pancreatic Cancer Dissemination: The Role of the Chemokine System
Current Pharmaceutical Design Biocompatible Europium Doped Hydroxyapatite Nanoparticles as a Biological Fluorescent Probe
Current Nanoscience Repositioning of RdRp Inhibitors Against HCV NS5B Polymerase Utilizing Structure-Based Molecular Docking
Combinatorial Chemistry & High Throughput Screening Ciprofloxacin Stress Proteome of the Extended-Spectrum β-lactamase Producing Escherichia coli from Slaughtered Pigs
Current Proteomics HSP90 Inhibitors: Multi-Targeted Antitumor Effects and Novel Combinatorial Therapeutic Approaches in Cancer Therapy
Current Medicinal Chemistry Gold Nanoparticles Conjugated with Glycopeptides for Lectin Detection and Imaging on Cell Surface
Protein & Peptide Letters Peripheral Mononuclear Cell Rejuvenation for Senescence Surveillance in Alzheimer Disease
Current Pharmaceutical Design